Cargando…

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus

Type 2 diabetes mellitus (T2DM) and cardiovascular disease are closely interconnected. We sought to determine the cardioprotective action of finerenone according to prior treatment with newer antidiabetics and glycemic status. We searched PubMed and Cochrane Library from inception to October 1, 2021...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patoulias, Dimitrios, Papadopoulos, Christodoulos, Karagiannis, Asterios, Vassilikos, Vassilios, Doumas, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Endocrine Society 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901958/ https://www.ncbi.nlm.nih.gov/pubmed/35144333 http://dx.doi.org/10.3803/EnM.2021.1296

Ejemplares similares

Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Colchicine for the prevention of COVID-19 “hard” outcomes: All that glitters is not gold
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Sodium-glucose co-transporter-2 inhibitor mediated cardio-protection: does increase of hematocrit finally matter? Sub-analysis of a prospective, observational study
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerations
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review
por: Papadopoulos, Christodoulos, et al.
Publicado: (2020)

Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Endothelial dysfunction and COVID-19: What's the true impact on surrogate outcomes?
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Meta-Analysis Addressing the Efficacy and Safety of Antiplatelet Agents in Patients With COVID-19
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7)
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?
por: Doumas, Michael, et al.
Publicado: (2020)

Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Time to assess the effects of sodium–glucose co‐transporter‐2 inhibitors on the ‘forgotten' right ventricle?
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

The Associations between Kidney Function and Sexual Dysfunction among Males and Females with Type 2 Diabetes Mellitus
por: Katsimardou, Alexandra, et al.
Publicado: (2023)

Red carpeting the newer antidiabetics
por: Gude, Dilip
Publicado: (2012)

A Rare Case of Lipomatous Hypertrophy of the Interventricular Septum
por: Papadopoulos, Christodoulos E., et al.
Publicado: (2016)

Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Iron therapy and severe arrhythmias in HFrEF: rationale, study design, and baseline results of the RESAFE‐HF trial
por: Bakogiannis, Constantinos, et al.
Publicado: (2023)

A Case of a Paracardial Osteophyte Causing Atrial Compression
por: Tzikas, Stergios, et al.
Publicado: (2016)

A Left Atrial Appendage Phantom Structure
por: Papadopoulos, Christodoulos E., et al.
Publicado: (2016)

Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin
por: Theofilis, Panagiotis, et al.
Publicado: (2022)

Newer antidiabetic drugs and calorie restriction mimicry
por: Kalra, Sanjay, et al.
Publicado: (2016)

Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action
por: Athyros, Vasilios Gabriel, et al.
Publicado: (2016)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients
por: Mudher Mikhael, Ehab
Publicado: (2016)

The Impact of Metabolic Syndrome Components on Erectile Function in Patients with Type 2 Diabetes
por: Katsimardou, Alexandra, et al.
Publicado: (2023)

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA(1c) and Insulin Use: An Analysis From the FIDELIO-DKD Study
por: Rossing, Peter, et al.
Publicado: (2022)

Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
por: Lv, Ruolin, et al.
Publicado: (2023)

Glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with renal complications
por: Huri, Hasniza Zaman, et al.
Publicado: (2015)

The Role of Finerenone in the Management of Diabetic Nephropathy
por: Veneti, Stavroula, et al.
Publicado: (2021)

Potassium management with finerenone: Practical aspects
por: Wanner, Christoph, et al.
Publicado: (2022)

Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus
por: Jin, Tao, et al.
Publicado: (2023)

Cardiorenal benefits of finerenone: protecting kidney and heart
por: González-Juanatey, José R., et al.
Publicado: (2023)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Homocysteine as a Predictor of Paroxysmal Atrial Fibrillation-Related Events: A Scoping Review of the Literature
por: Charalampidis, Panagiotis, et al.
Publicado: (2022)

Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications
por: Huri, Hasniza Zaman, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_l13cuql8fu3sm6f4h8sf5sbm5b